Abstract
Background: Sofosbuvir (SOF) was approved in Europe in January 2014. However, outcomes of SOF based therapy in patients on OST in comparison to NON-OST were not systematically studied. Here, we present corresponding real-life data on SOF-based treatments from Germany.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
